<DOC>
	<DOCNO>NCT00046683</DOCNO>
	<brief_summary>This Phase III , open-label , multicenter , randomize , comparative study Campath versus chlorambucil front line therapy patient progressive B-Cell Lymphocytic Leukemia ( B-CLL ) . Eligible patient must previously untreated , Rai stage I-IV disease , experience progression B-CLL require treatment . Patients meet eligibility criterion may randomize 1:1 basis receive either Campath chlorambucil . An estimated 284 patient ( 142 per treatment arm ) approximately 40 investigational site randomize one two treatment arm .</brief_summary>
	<brief_title>Efficacy/Safety Frontline Alemtuzumab ( Campath , MabCampath ) v Chlorambucil Patients With Progressive B-Cell Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Histopathologically confirm diagnosis BCLL CD5 , CD19 , CD23 positive clone . Rai Stage I IV disease evidence progression evidence presence one following:1 . Diseaserelated B symptom ( fever great 38 celsius ( 100.5 F ) great equal 2 week without evidence infection , night sweat without evidence infection , weight loss &gt; 10 % within previous 6 month . 2 . Evidence progression marrow failure manifest : a. decrease hemoglobin &lt; 11g/dL b. decrease platelet count &lt; 100x10 ninth/L within previous 6 month c. decrease absolute neutrophil count ( ANC ) &lt; 1.0x10 ninth/L within previous 6 month . 3 . Progressive splenomegaly &gt; 2 cm leave costal margin organomegaly progressive increase 2 consecutive clinic visit great equal 2 week apart . 4 . Progressive lymphadenopathy least 5 site involvement either two node least 2cm long diameter one node great equal 5cm long diameter progressive increase 2 consecutive visit great equal week apart . 5 . Progressive lymphocyte increase &gt; 50 % 2month period , anticipate double time le 6 month . Received previous chemotherapy BCLL . Life expectancy least 12 week . WHO performance status 0 , 1 , 2 . Serum creatinine less equal 2.0 time institutional upper limit normal ( ULN ) value . Adequate liver function indicate total bilirubin , AST , ALT le equal 2 time institutional ULN value , unless directly attributable disease . Female patient childbearing potential must negative serum pregnancy test within 2 week prior randomization . Male female patient must agree use effective contraceptive method study treatment , appropriate , minimum 6 month study therapy . Signed , write informed consent . 18 year age old . ANC le 500 million per liter platelet count le 10 billion per liter . Medical condition require chronic use oral corticosteroid . Autoimmune thrombocytopenia . Previous bone marrow transplant . Use investigational agent within previous 30 day . Positive HIV . Past history anaphylaxis follow exposure rat mousederived complementary determine region ( CDR ) graft humanized monoclonal antibody . Active infection . Serious cardiac pulmonary disease could interfere ability participate study . Recent document ( 2 year ) active tuberculosis ( TB ) , current active TB , currently receive antituberculosis medication . Active secondary malignancy . Central nervous system involvement CLL . Positive quantitative CMV PCR assay ( use laboratory normal range ) . A diagnosis mantle cell lymphoma . Other severe , concurrent disease mental disorder . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adult acute leukemia</keyword>
	<keyword>Adult chronic leukemia</keyword>
	<keyword>Childhood leukemia</keyword>
	<keyword>Campath</keyword>
	<keyword>Alemtuzumab</keyword>
</DOC>